Literature DB >> 33938090

Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review.

Ke-Tao Jin1, Wen-Lin Du2,3, Huan-Rong Lan4, Yu-Yao Liu1, Chun-Sen Mao1, Jin-Lin Du1, Xiao-Zhou Mou3.   

Abstract

Immunotherapy has revolutionized cancer treatment, however, not all tumor types and patients are completely responsive to this approach. Establishing predictive pre-clinical models would allow for more accurate and practical immunotherapeutic drug development. Mouse models are extensively used as in vivo system for biomedical research. However, due to the significant differences between rodents and human, it is impossible to translate most of the findings from mouse models to human. Pharmacological development and advancing personalized medicine using patient-derived xenografts relies on producing mouse models in which murine cells and genes are substituted with their human equivalent. Humanized mice (HM) provide a suitable platform to evaluate xenograft growth in the context of a human immune system. In this review, we discussed recent advances in the generation and application of HM models. We also reviewed new insights into the basic mechanisms, pre-clinical evaluation of onco-immunotherapies, current limitations in the application of these models as well as available improvement strategies. Finally, we pointed out some issues for future studies.
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  human specificity; humanized mice; immunology; immunotherapy; patient-derived xenografts

Year:  2021        PMID: 33938090     DOI: 10.1111/cas.14934

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice.

Authors:  Christina Bruss; Kerstin Kellner; Olaf Ortmann; Stephan Seitz; Gero Brockhoff; James A Hutchinson; Anja Kathrin Wege
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

Review 2.  Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review.

Authors:  Tomohito Tanaka; Ruri Nishie; Shoko Ueda; Shunsuke Miyamoto; Sousuke Hashida; Hiromi Konishi; Shinichi Terada; Yuhei Kogata; Hiroshi Sasaki; Satoshi Tsunetoh; Kohei Taniguchi; Kazumasa Komura; Masahide Ohmichi
Journal:  J Clin Med       Date:  2022-05-06       Impact factor: 4.964

Review 3.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

Review 4.  Large Animal Models of Breast Cancer.

Authors:  Pinaki Mondal; Katie L Bailey; Sara B Cartwright; Vimla Band; Mark A Carlson
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

5.  N-of-1 Healthcare: Challenges and Prospects for the Future of Personalized Medicine.

Authors:  Kui You; Peter Wang; Dean Ho
Journal:  Front Digit Health       Date:  2022-02-11

6.  Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model.

Authors:  Harinarayanan Janakiraman; Scott A Becker; Alexandra Bradshaw; Mark P Rubinstein; Ernest Ramsay Camp
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.